Q1 2024 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2024-05-15 · accession 0001172661-24-002523
$641.6M
Reported value
35
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 64135M105 | NGNE | NEUROGENE INC | $51.1M | 7.97% | 1,004,291 | Common | SHARED |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $44.7M | 6.97% | 1,128,499 | Common | SHARED |
| M96088105 | URGN | UROGEN PHARMA LTD | $39.3M | 6.13% | 2,620,545 | Common | SHARED |
| 00370M103 | ABVX | ABIVAX SA | $35.6M | 5.55% | 2,488,483 | Common | SHARED |
| 30052C107 | EOLS | EVOLUS INC | $34.3M | 5.35% | 2,450,000 | Common | SHARED |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $27.6M | 4.30% | 1,851,864 | Common | SHARED |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $26.6M | 4.14% | 400,000 | Common | SHARED |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $26.2M | 4.09% | 887,690 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $23.4M | 3.64% | 1,335,000 | Common | SHARED |
| 032724106 | ANAB | ANAPTYSBIO INC | $22.0M | 3.43% | 976,981 | Common | SHARED |
| 29664W105 | ESPR | ESPERION THERAPEUTICS INC NE | $21.4M | 3.34% | 8,000,000 | Common | SHARED |
| 457669307 | INSM | INSMED INC | $21.0M | 3.28% | 775,585 | Common | SHARED |
| 03940C100 | ACLXGBX | ARCELLX INC | $20.9M | 3.25% | 300,000 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $19.6M | 3.06% | 456,148 | Common | SHARED |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $18.8M | 2.93% | 2,000,000 | Common | SHARED |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $18.8M | 2.92% | 625,000 | Common | SHARED |
| 69012T305 | OTLK | OUTLOOK THERAPEUTICS INC | $17.7M | 2.75% | 1,480,000 | Common | SHARED |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $17.6M | 2.75% | 1,495,500 | Common | SHARED |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $15.7M | 2.45% | 1,728,723 | Common | SHARED |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $15.7M | 2.45% | 1,264,920 | Common | SHARED |
| 23282W605 | CYTK | CYTOKINETICS INC | $14.2M | 2.21% | 202,202 | Common | SHARED |
| 68404V100 | — | OPTINOSE INC | $12.8M | 2.00% | 8,786,318 | Common | SHARED |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $12.0M | 1.86% | 407,550 | Common | SHARED |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $10.4M | 1.62% | 150,000 | Common | SHARED |
| N5749R100 | 2GH | MERUS N V | $10.1M | 1.57% | 223,288 | Common | SHARED |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $9.8M | 1.53% | 1,858,735 | Common | SHARED |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $8.6M | 1.34% | 1,309,975 | Common | SHARED |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $7.5M | 1.16% | 115,000 | Common | SHARED |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $7.4M | 1.16% | 1,166,667 | Common | SHARED |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $7.1M | 1.11% | 1,343,628 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $7.1M | 1.10% | 2,757,740 | Common | SHARED |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $5.2M | 0.81% | 500,000 | Common | SHARED |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $4.7M | 0.74% | 125,000 | Common | SHARED |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $3.7M | 0.58% | 150,000 | Common | SHARED |
| 04335A105 | ARVN | ARVINAS INC | $2.9M | 0.46% | 71,113 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.